How much profit has CRISPR Therapeutics made this year?
CRISPR Therapeutics has made -448.78 M USD this year.
In 2024, CRISPR Therapeutics's profit amounted to -448.78 M USD, a 192.15% increase from the -153.61 M USD profit recorded in the previous year.
YEAR | NET INCOME (undefined USD) |
---|---|
2030e | 3.38 |
2029e | 1.03 |
2028e | 0.42 |
2027e | 0.08 |
2026e | -0.26 |
2025e | -0.44 |
2024e | -0.45 |
2023 | -0.15 |
2022 | -0.65 |
2021 | 0.38 |
2020 | -0.35 |
2019 | 0.07 |
2018 | -0.17 |
2017 | -0.07 |
2016 | -0.02 |
2015 | -0.03 |
2014 | -0.01 |
3 years
5 years
10 years
25 Years
Max
Gain insights into CRISPR Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by CRISPR Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects CRISPR Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.
Observe the yearly bars to understand the annual performance and growth of CRISPR Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
The expected values for the forthcoming years offer investors a glimpse into CRISPR Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Leveraging the comparison between Revenue and EBIT helps in assessing CRISPR Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on CRISPR Therapeutics’s growth potential.
Date | CRISPR Therapeutics Revenue | CRISPR Therapeutics EBIT | CRISPR Therapeutics Net Income |
---|---|---|---|
2030e | 8.65 B undefined | 3.77 B undefined | 3.38 B undefined |
2029e | 3.6 B undefined | 2.12 B undefined | 1.03 B undefined |
2028e | 2.15 B undefined | 420.38 M undefined | 415.64 M undefined |
2027e | 1.46 B undefined | 60.91 M undefined | 82.8 M undefined |
2026e | 770.63 M undefined | -206.59 M undefined | -259.04 M undefined |
2025e | 157.52 M undefined | -469.99 M undefined | -439.9 M undefined |
2024e | 25.15 M undefined | -568.39 M undefined | -448.78 M undefined |
2023 | 371.21 M undefined | -222.54 M undefined | -153.61 M undefined |
2022 | 1.2 M undefined | -673.2 M undefined | -650.2 M undefined |
2021 | 915 M undefined | 373.5 M undefined | 377.7 M undefined |
2020 | 700,000 undefined | -354.4 M undefined | -348.9 M undefined |
2019 | 289.6 M undefined | 46.7 M undefined | 66.9 M undefined |
2018 | 3.1 M undefined | -158.9 M undefined | -165 M undefined |
2017 | 41 M undefined | -64.6 M undefined | -68.4 M undefined |
2016 | 5.2 M undefined | -68.1 M undefined | -23.2 M undefined |
2015 | 200,000 undefined | -25.7 M undefined | -25.5 M undefined |
2014 | 0 undefined | -6.6 M undefined | -7 M undefined |
Revenue | EBIT | Net Income | |
---|---|---|---|
2014 | 0 USD | -6.6 M USD | -7 M USD |
2015 | 200,000 USD | -25.7 M USD | -25.5 M USD |
2016 | 5.2 M USD | -68.1 M USD | -23.2 M USD |
2017 | 41 M USD | -64.6 M USD | -68.4 M USD |
2018 | 3.1 M USD | -158.9 M USD | -165 M USD |
2019 | 289.6 M USD | 46.7 M USD | 66.9 M USD |
2020 | 700,000 USD | -354.4 M USD | -348.9 M USD |
2021 | 915 M USD | 373.5 M USD | 377.7 M USD |
2022 | 1.2 M USD | -673.2 M USD | -650.2 M USD |
2023 | 371.21 M USD | -222.54 M USD | -153.61 M USD |
2024e | 25.15 M USD | -568.39 M USD | -448.78 M USD |
2025e | 157.52 M USD | -469.99 M USD | -439.9 M USD |
2026e | 770.63 M USD | -206.59 M USD | -259.04 M USD |
2027e | 1.46 B USD | 60.91 M USD | 82.8 M USD |
2028e | 2.15 B USD | 420.38 M USD | 415.64 M USD |
2029e | 3.6 B USD | 2.12 B USD | 1.03 B USD |
2030e | 8.65 B USD | 3.77 B USD | 3.38 B USD |
3 years
5 years
10 years
25 Years
Max
The gross margin, expressed as a percentage, delineates the gross profit made from the CRISPR Therapeutics's sales revenue. A higher gross margin percentage indicates that the CRISPR Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT margin represents the CRISPR Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
The revenue margin demonstrates the CRISPR Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the CRISPR Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the CRISPR Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the CRISPR Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
CRISPR Therapeutics Gross margin | CRISPR Therapeutics Profit margin | CRISPR Therapeutics EBIT margin | CRISPR Therapeutics Profit margin |
---|---|---|---|
2030e | 0 % | 43.58 % | 39.05 % |
2029e | 0 % | 58.91 % | 28.56 % |
2028e | 0 % | 19.55 % | 19.33 % |
2027e | 0 % | 4.17 % | 5.67 % |
2026e | 0 % | -26.81 % | -33.61 % |
2025e | 0 % | -298.37 % | -279.27 % |
2024e | 0 % | -2,259.83 % | -1,784.25 % |
2023 | 0 % | -59.95 % | -41.38 % |
2022 | 0 % | -56,100 % | -54,183.33 % |
2021 | 0 % | 40.82 % | 41.28 % |
2020 | 0 % | -50,628.57 % | -49,842.86 % |
2019 | 0 % | 16.13 % | 23.1 % |
2018 | 0 % | -5,125.81 % | -5,322.58 % |
2017 | 0 % | -157.56 % | -166.83 % |
2016 | 0 % | -1,309.62 % | -446.15 % |
2015 | 0 % | -12,850 % | -12,750 % |
2014 | 0 % | 0 % | 0 % |
Gross margin | EBIT margin | Profit margin | |
---|---|---|---|
2014 | 0 % | 0 % | 0 % |
2015 | 0 % | -12,850 % | -12,750 % |
2016 | 0 % | -1,309.62 % | -446.15 % |
2017 | 0 % | -157.56 % | -166.83 % |
2018 | 0 % | -5,125.81 % | -5,322.58 % |
2019 | 0 % | 16.13 % | 23.1 % |
2020 | 0 % | -50,628.57 % | -49,842.86 % |
2021 | 0 % | 40.82 % | 41.28 % |
2022 | 0 % | -56,100 % | -54,183.33 % |
2023 | 0 % | -59.95 % | -41.38 % |
2024e | 0 % | -2,259.83 % | -1,784.25 % |
2025e | 0 % | -298.37 % | -279.27 % |
2026e | 0 % | -26.81 % | -33.61 % |
2027e | 0 % | 4.17 % | 5.67 % |
2028e | 0 % | 19.55 % | 19.33 % |
2029e | 0 % | 58.91 % | 28.56 % |
2030e | 0 % | 43.58 % | 39.05 % |
The profit margins of CRISPR Therapeutics represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of CRISPR Therapeutics's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Evaluating CRISPR Therapeutics's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
CRISPR Therapeutics's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
When CRISPR Therapeutics’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
CRISPR Therapeutics has made -448.78 M USD this year.
The profit has increased by 192.15% compared to last year increased
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
CRISPR Therapeutics publishes its earnings in the form of quarterly or annual reports.
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
The profits of CRISPR Therapeutics are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
You can learn more about the earnings of CRISPR Therapeutics by reviewing the quarterly or annual reports or following the company presentations.
Over the past 12 months, CRISPR Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, CRISPR Therapeutics is expected to pay a dividend of 0 USD.
The current dividend yield of CRISPR Therapeutics is .
CRISPR Therapeutics pays a quarterly dividend. This is distributed in the months of .
CRISPR Therapeutics paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
CRISPR Therapeutics is assigned to the 'Health' sector.
To receive the latest dividend of CRISPR Therapeutics from 11/11/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/11/2024.
The last dividend was paid out on 11/11/2024.
In the year 2023, CRISPR Therapeutics distributed 0 USD as dividends.
The dividends of CRISPR Therapeutics are distributed in USD.
Our stock analysis for CRISPR Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CRISPR Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.